# GLAUKOS Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/GLAUKOS Corp). ## Overview Glaukos Corp develops and commercializes ophthalmic therapies and devices focused on glaucoma, corneal disorders, and emerging anterior/posterior segment treatments. The company sells products such as iStent, iDose TR, Photrexa, and Epioxa through direct sales in the U.S. and a mix of subsidiaries and distributors internationally. ## Products & services • iStent family of glaucoma micro-invasive surgical devices • iDose TR intracameral travoprost implant • Photrexa and related corneal cross-linking drug formulations • Epioxa keratoconus treatment • Proprietary bioactivation systems and glaucoma accessories • Pipeline therapies including GLK-401 and GLK-411 - **Glaucoma surgical devices** (60%) — Micro-invasive glaucoma surgery products used by surgeons to reduce intraocular pressure. - **Procedural pharmaceuticals** (23%) — Drug-device therapies such as iDose TR used in ophthalmic procedures. - **Corneal cross-linking therapies** (15%) — Photrexa and Epioxa products used in keratoconus and corneal disorder treatment. - **Pipeline and other ophthalmology programs** (2%) — Clinical and pre-clinical programs targeting broader ophthalmic indications. - iStent family of micro-invasive glaucoma surgery devices - iDose TR intracameral travoprost implant - Photrexa and related corneal cross-linking formulations - Epioxa incision-free keratoconus therapy - Proprietary bioactivation systems and glaucoma accessories - Pipeline programs GLK-401 and GLK-411 ## Customers Glaukos sells primarily to ophthalmic surgeons and other eye care professionals, with end-user demand concentrated in ambulatory surgery centers, hospitals, and physician private practices. In the U.S. it relies mainly on a direct sales force, while internationally it uses direct subsidiaries and distributors where it lacks a full commercial footprint. - **Ambulatory surgery centers** (primary) — Buy iStent, iDose TR, and corneal products for outpatient ophthalmic procedures and efficiency. - **Hospitals** (primary) — Purchase ophthalmic devices and therapies for surgical and specialty eye care programs. - **Physician private practices** (primary) — Use Glaukos products for glaucoma and corneal treatment in office-based care settings. - **International distributors** (secondary) — Buy and resell products in countries where Glaukos lacks direct commercial operations. - **Ophthalmic surgeons and eye care professionals** (primary) — Influence product adoption through procedure preference, training, and clinical acceptance. - Ambulatory surgery centers buy for high-volume ophthalmic procedures - Hospitals use products for surgical glaucoma and corneal care - Physician private practices adopt therapies for office-based eye care - Ophthalmic surgeons are the key clinical decision-makers - International distributors serve markets without direct commercial presence ## Geography Glaukos generates most of its revenue in the United States, with the remainder coming from international markets. The company sells directly in the U.S. and uses direct subsidiaries plus independent distributors abroad, which makes international growth dependent on local commercial coverage and regulatory access. - **United States** (74%) — Management disclosed U.S. sales as 74% of net sales in 2025. - **International** (26%) — Management disclosed international sales as 26% of net sales in 2025. - U.S. accounted for 74% of net sales in 2025 - International markets accounted for 26% of net sales in 2025 - U.S. sales are mainly through a direct sales organization - International sales use subsidiaries and distributors in selected countries - Huntsville, Alabama is a key planned R&D and manufacturing expansion site ## Strategy Glaukos is expanding beyond its core glaucoma franchise by commercializing iDose TR and launching Epioxa while advancing earlier-stage ophthalmology pipeline assets. It is also investing in manufacturing and R&D capacity, including a planned Huntsville facility, to support future product demand and broader global commercialization. - **Commercialize iDose TR successfully** (short-term) — It is a newly commercialized product and a key growth driver, but adoption and reimbursement must scale. - **Launch Epioxa in early 2026** (short-term) — FDA approval expands the corneal franchise and diversifies revenue beyond glaucoma. - **Expand manufacturing and R&D footprint** (medium-term) — Capacity is needed to meet demand and support a broader product portfolio. - **Advance pipeline programs** (medium-term) — Pipeline success could extend the company into larger ophthalmology markets. - Scale iDose TR adoption through physician training and reimbursement access - Launch Epioxa and build a new keratoconus treatment franchise - Expand manufacturing capacity to support product demand growth - Advance GLK-401 and GLK-411 to broaden the ophthalmology pipeline - Use direct sales in core markets and distributors where needed ## Risks Glaukos depends heavily on the commercial success of a small number of products, especially iDose TR and Epioxa, so launch execution and reimbursement are critical. The company also faces regulatory, manufacturing, and competitive risks across ophthalmology, where larger peers and alternative therapies can pressure adoption and pricing. - **Commercial failure of iDose TR** [high] — The product is newly commercialized and needs physician adoption, reimbursement, and manufacturing scale. - **Commercial failure of Epioxa** [high] — The product is newly approved and must establish clinical acceptance and payer support. - **Manufacturing capacity constraints** [medium] — Growth requires expansion of production and facility build-out, which can delay supply or raise costs. - **Competitive pressure in ophthalmology** [high] — Large medtech and pharma companies compete in glaucoma, corneal disorders, and future pipeline indications. - **International commercial execution** [medium] — Some markets rely on distributors rather than direct operations, which can limit control and growth. - iDose TR adoption depends on physician training and payer coverage - Epioxa launch risk is high because it is newly approved and unproven commercially - Manufacturing scale-up could constrain supply if demand rises faster than capacity - Competition is intense in glaucoma, corneal, and future pipeline markets - International growth depends on distributors and local regulatory access ## Accounting Revenue is recognized when control transfers, but reported sales are affected by rebates, returns, discounts, and warranty replacements, which can shift revenue between periods. Investors should also watch inventory reserves, lease accounting, and estimates tied to manufacturing expansion, as well as the potential for impairment or acquisition-related accounting if the company continues to invest in new facilities and technologies. - **Revenue recognition and variable consideration** — Can shift reported revenue and margins period to period - **Inventory reserves** — Can materially affect gross margin when demand or product mix changes - **Lease accounting** — Affects balance sheet liabilities and cash flow presentation - **Capital expenditures and facility build-out** — Raises depreciation, capitalized asset balances, and future fixed-cost burden - Revenue net of rebates, returns, discounts, and incentives - Point-in-time revenue recognition for product sales - Inventory reserves for excess and obsolete stock - Lease obligations affect reported liabilities and cash needs - Capitalized facility and equipment spending affects depreciation --- *Last updated: 2026-04-28T20:10:06.259280+00:00*